Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
-
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
-
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
-
Prime Minister Celebrates Opening of Cambodia's State-of-the-art International Airport
-
WePlay x Care Bears Halloween Carnival Party Officially Kicks Off!
-
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
-
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
-
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The Whole FX Team is Now in Full Sprint Mode for the Year-End Off-Line Target for the Company’s First FX Super One Vehicle
-
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
-
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
-
The Republic of Korea Selects L3Harris for Airborne Early Warning and Control Aircraft Program
-
Leading Competition Economist Dr. Luke Wainscoat Joins The Brattle Group
-
Kering and L’Oréal forge an alliance in beauty and wellness
-
United States Antimony Corporation Submits Indicative Proposal to Acquire 100% of Larvotto Resources Limited Located in Australia
-
CLARINS & V MAGAZINE CELEBRATE HIGH-PERFORMANCE BEAUTY WITH A STAR-STUDDED GOLDEN HOUR EVENT IN AUSTIN
-
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
-
Vantage Drilling International Ltd. – Announcement of Contract Termination
-
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
-
FreightTracker Receives Strategic Growth Investment from Arcadea Group
-
Keo World Triumphs at the Le Fonti Awards 2025 with Its Revolutionary B2B Credit Solution: The Fintech Transforming Finance
-
Important Notice to Long-Term Shareholders of Baxter International Inc. (BAX): Grabar Law Office Investigates Claims on Your Behalf
-
American Airlines and Citi Launch the Citi / AAdvantage Globe Mastercard
-
Nexzen Extracts — The Best THCA Brand Launches Spooky Halloween Sale with Up to 45% Off Sitewide
-
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
-
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
-
Rockcliffe Labs Launches Canada’s First Venture-Building Platform for Biotechnology and Life Sciences with Mission to Create 100 Companies
-
iOncologi Secures Foundational U.S. Patent as Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival with Cancer Immunotherapy
-
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
-
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the
-
VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma
-
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
-
Amdark Limited Expands Global Reach in Fighting Crypto and Investment Scams Across Canada, UK, and USA
-
Global Times: Over 400 senior guests from over 30 countries, regions to attend conference of Financial Street Forum 2025 in Beijing: organizers
-
/C O R R E C T I O N -- Spinogenix/
-
United Imaging Marks Five Years Since the Opening of its Global Showroom In North America with a Record Number of U.S. Customer Visits
-
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
-
Max Stock Limited releases an immediate report on holdings of interested parties and senior officers as of September 30, 2025
-
HDAI to announce AI tools that drive quality outcomes at HLTH 2025
-
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
-
PayrollOrg's Educational Institutions Payroll Conference to Equip Higher Ed Payroll Professionals with Essential Compliance and Technology Insights
-
Innovation Rooted in Listening: Relaxure Custom Pergolas Bring Smart Comfort to Every Home
-
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-O
-
SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at E
-
Startuprad.io Launches Startup AI Concierge for Europe's Startup Ecosystem
-
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
-
What 50 Failed Startups Teach About Modern Management
-
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
-
Historical Adventure Series ‘Adventures in Time' Inspires Young Readers to Explore the Past
-
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
-
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
